KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).

Noriko Mitome, Akira Hamada, Masashi Wakabayashi, Takeshi Uozumi, Hidehito Horinouchi, Mitsuhiro Isaka, Masaya Yotsukura, Keiju Aokage, Haruhiko Fukuda, Shun-Ichi Watanabe, Yasuhiro Tsutani, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)

Clin Lung Cancer 27(5) 5-10

PMID42107198
PMCID-
DOI10.1016/j.cllc.2026.04.006
发表日期2026-05-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: The standard treatment for resectable non-small cell lung cancer (NSCLC) has traditionally been upfront surgery, followed by adjuvant therapy according to pathological stage. Although recent trials have demonstrated the superiority of surgery after neoadjuvant chemoimmunotherapy over chemotherapy alone, studies directly comparing it with upfront surgery remain lacking. This trial aims to determine the optimal perioperative treatment strategy for resectable NSCLC. METHODS: This is a multicenter, randomized, phase III trial designed to assess the superiority of neoadjuvant chemoimmunotherapy over upfront surgery followed by adjuvant therapy in terms of overall survival in patients with resectable clinical stage II-III NSCLC. Patients are randomized in a 1:1 ratio to receive either (1) upfront surgery followed by cisplatin-based chemotherapy (every 3 weeks for 4 cycles) and immune checkpoint inhibitor monotherapy (up to 1 year for patients with PD-L1 TPS≥1%) or (2) neoadjuvant nivolumab plus platinum-based chemotherapy (every 3 weeks for 3 cycles) followed by surgery. The primary endpoint is the overall survival. Secondary endpoints include progression-free survival, time to distant metastasis, objective response rate to neoadjuvant therapy, and adverse events. A total of 330 patients will be enrolled over 5 years. The trial was initiated in March 2025 and registered in the Japan Registry of Clinical Trials (study number: jRCTs031240747). CONCLUSIONS: As immunotherapy has become an integral component of NSCLC management in the perioperative setting, this trial is expected to provide critical evidence to refine optimal perioperative treatment strategies for patients with resectable stage II-III NSCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。